Presented by
IVBM Event Coverage
The Expanding Frontier of Cardiometabolic Care
Clinicians gathered in Houston, Texas, to examine how newer drug options are reshaping cardiometabolic care and how integrated health systems can put evidence into practice.
The Unfinished Work of Value-Based Cancer Care
Ohio cancer care leaders identified persistent gaps in quality, pharmacy infrastructure, bispecific access, and biomarker testing at a May 2026 summit.
CAR T-Cell Therapy, Biomarkers, Clinical Trials, and Bladder Cancer Advances
Discussions highlighted implementing innovative treatments and ensuring patients treated in the community setting have equitable access to advanced therapeutics.
Hayley Knollman, MD, Highlights Growing Role of Patient Preferences in Breast Cancer Care
Shared decision-making and quality of life are increasingly shaping metastatic breast cancer care amid persistent social barriers, notes Hayley Knollman, MD.
Patient-Centered Oncology Care, Guidelines, and Expertise Drive Value in Practice: Seungjean Chai, MD
At the IVBM Charlotte event, Seungjean Chai, MD, emphasized that patient-centered design, guidelines, and subspecialty expertise are essential to high-value oncology care.
Operationalizing BiTE Therapies in Community Oncology: Kaitlyn Schomberg, PharmD
Kaitlyn Schomberg, PharmD, discusses BiTE therapy adoption, toxicity management, and care coordination in community oncology settings.
Multiple Myeloma Sequencing Evolves With CAR T, MRD Insights: Sylvester Homsy, MD
CAR-T and bispecifics in multiple myeloma are reshaping sequencing, enabling earlier use, but access and standardization challenges remain, per Sylvester Homsy, MD.
Access, Timing, Workflow Challenges Shape Biomarker Testing in NSCLC: Parth Desai, MBBS, MD
Parth Desai, MBBS, MD, discusses how clinicians balance liquid biopsy, tissue testing, and fast-start chemo to personalize non–small cell lung cancer treatment.
Decentralized Trials Hold Promise, but Cost, Infrastructure Challenges Remain: Arturo Loaiza-Bonilla, MD
Clinical trials are evolving toward decentralized, patient-centered models, but enrollment challenges, outdated protocols, and infrastructure gaps persist.
Emerging Therapies in Multiple Myeloma Shift Focus Toward Cure: Asya Nina Varshavsky-Yanovsky, MD, PhD
New myeloma therapies—CAR T, bispecific antibodies, and oral CELMoDs—expand options, protect QOL, and raise hopes of cure, notes Asya Nina Varshavsky-Yanovsky, MD, PhD.
Staging, ctDNA, and the Art of Personalizing Metastatic Breast Cancer Therapy: Hayley Knollman, MD
Hayley Knollman, MD, explains how ctDNA and genomic testing impact ER-positive metastatic breast cancer care, guiding sequencing decisions amid evolving HER2 categories.
Shawn Davis, MD, on Access, Coverage, and the Future of Obesity Therapy
Oral semaglutide hasn't shifted prescribing as expected. Shawn Davis, MD, discusses what access and policy changes are needed to close the coverage gap.
Building Trust, Not Just Enrollment: Amy Leader, DrPH, MPH, on Community Trial Success
Amy Leader, DrPH, MPH, explains that trust is key to clinical trial enrollment at an Institute for Value-Based Medicine event in Philadelphia.
Nurse Navigation, Reflex Testing Key to Closing Molecular Testing Gaps: Christopher D'Avella, MD
Equity gaps in lung cancer molecular testing persist; reflex testing and nurse navigation speed care, while coverage and access barriers stall outcomes
Lung Cancer Molecular Testing Nears 70%, Still Falls Short of Universal Use: Christopher D'Avella, MD
Reflex molecular testing and nurse navigation cut delays in lung cancer care, helping more patients get targeted results before first-line therapy, says Christopher D'Avella, MD.
Shawn Davis, MD, on How Payers Should Think About Obesity Treatment Return on Investment
With obesity costing $1.4 trillion annually, Shawn Davis, MD, argues the return on treatment investment is clear if we build systems to measure it.
Operationalizing Seamless Care Between Community and Academic Centers: Turab Mohammed, MD
Learn how CRS and ICANS present in patients undergoing immunotherapy and what clinicians should know about recognizing and managing these toxicities.
A Multilevel Strategy for Diversity in Clinical Trials: Tina Bhatnagar, DO
Tina Bhatnagar, DO, speaks to the importance of diversity in clinical trials and the need to remove barriers, enroll underrepresented backgrounds, and reflect real-world health conditions.
Closing Breast Cancer Screening Gaps Through Community Outreach, Credible Messaging: Kathrin Dvir, MD, MSc
Kathrin Dvir, MD, MSc, concludes by highlighting the importance of outreach, education, and trusted messaging to improve breast cancer screening adherence.
Ensuring Access to Advanced Multiple Myeloma Treatments Amid Delivery Challenges: Ameet Patel, MD
Ameet Patel, MD, concludes by outlining strategies to overcome operational, financial, and payer challenges in delivering advanced multiple myeloma therapies.
Balancing Safety, Logistics in Multiple Myeloma Treatment Settings: Ameet Patel, MD
Ameet Patel, MD, explains how multiple myeloma treatment settings depend on safety, logistics, and patient needs.
Adapting CAR-T and Cell Therapies for Community Oncology: Biagio Ricciuti, MD
Ricciuti explains why advanced adoptive cell therapies require major infrastructure, toxicity management, and strong academic–community collaboration.
Access Barriers Limit Community Adoption of Novel Therapies: Biagio Ricciuti, MD
Biagio Ricciuti, MD, discusses how access challenges and toxicity concerns slow the rollout of new T-cell engager therapies from academic centers into community oncology.
Bringing Academic Oncology Best Practices to Community Care: Anasuya Gunturi, MD, PhD
Anasuya Gunturi, MD, PhD, explains how academic–community partnerships help deliver complex oncology services closer to home.
Oncology Pharmacy Is Critical to Modern Cancer Care: Kenneth Komorny, PharmD, BCPS
As more oral cancer therapies become available, medically integrated dispensing models are increasingly vital, says Kenneth Komorny, PharmD, BCPS.
Bridging the Academic-Community Gap in Cancer Care: Andrew Yee, MD
Andrew Yee, MD, explains how academic centers can share practical oncology best practices that community hospitals can implement sustainably.
Debunking Myths to Boost Clinical Trial Enrollment Diversity: Susan Vadaparampil, PhD, MPH
Susan Vadaparampil, PhD, MPH, explains that aligning clinical trials with community needs can improve enrollment diversity.
Academic–Community Oncology Partnerships Improve Access: Anasuya Gunturi, MD, PhD
Community-academic collaboration can reduce access burdens and strengthen continuity of care, says Anasuya Gunturi, MD, PhD.
High-Performing MID Programs Integrate Pharmacists Into Oncology Care Teams: Q&A With Osama Abdelghany, PharmD
Osama Abdelghany, PharmD, explains how medically integrated dispensing improves oncology workflows, patient access, and outcomes through EMR-driven care.
MID Models Foster Patient Trust, Boost Adherence: Kenneth Komorny, PharmD, BCPS
Medically integrated dispensing (MID) models help build patient trust in pharmacists, which can help improve adherence, explains Kenneth Komorny, PharmD, BCPS.
